CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Aldeyra Therapeutics Presents Reproxalap Regulatory Update in Corporate Overview

By Public Technologies
  • Aldeyra Therapeutics submitted a formal dispute resolution request for reproxalap in dry eye disease following three FDA complete response letters.
  • The latest FDA letter found insufficient evidence of effectiveness but did not request further clinical trials.
  • A meeting with the FDA's Office of New Drugs is expected in the fourth quarter of 2026.
  • Cash and cash equivalents totaled $41 million as of September 30, 2026, sufficient to fund operations into 2029.
  • AbbVie's licensing option includes a $100 million upfront payment less option fees, with a further $100 million contingent on FDA approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk